Gut Microbiota and the Roles of Probiotics during COVID-19 Pandemic
Keywords:
microbiota, microbiome, viral respiratory tract infection, coronavirus 2019, COVID-19, probioticsAbstract
Gut microbiota plays an important role in the development and modulation of the immune response. A coronavirus infection can cause dysbiosis of the gut microbiota and elicit a hyper-inflammatory response to the coronavirus disease 2019 (COVID-19), which may contribute to the development of severe pneumonia and cause adult respiratory distress syndrome (ARDS). Many studies have documented the beneficial role of probiotics in viral respiratory tract infections, including prevention, reduced symptoms, improved immune response to vaccination, and decreased mortality. However, due to the relative limited data available, the recommendations regarding the role of probiotics in COVID-19 treatment cannot be made at this time.
References
Abbott A. Scientists bust myth that our bodies have more bacteria than human cells. Nature [Internet]. 2016; Available from: https://www.nature.com/articles/nature.2016.19136
Villanueva-Millán MJ, Pérez-Matute P, Oteo JA. Gut microbiota: a key player in health and disease. A review focused on obesity. J Physiol Biochem. 2015;71(3):509–25.
Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027–31.
Yamashita T, Emoto T, Sasaki N, Hirata KI. Gut microbiota and coronary artery disease. Int Heart J. 2016;57(6):663–71.
Emoto T, Yamashita T, Sasaki N, Hirota Y, Hayashi T, So A, et al. Analysis of gut microbiota in coronary artery disease patients: A possible link between gut microbiota and coronary artery disease. J Atheroscler Thromb. 2016;23(8):908–21.
Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444(7122):1022–3.
Gurung M, Li Z, You H, Rodrigues R, Jump DB, Morgun A, et al. Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine. 2020;51:102590.
Vangoitsenhoven R, Cresci GAM. Role of microbiome and antibiotics in autoimmune diseases. Nutr Clin Pract. 2020;35(3):406–16.
Gill N, Finlay BB. The gut microbiota: challenging immunology. Nat Rev Immunol. 2011;11(10):636–7.
Hill DA, Artis D. Intestinal bacteria and the regulation of immune cell homeostasis. Annu Rev Immunol. 2010;28:623–67.
Hamada H, Hiroi T, Nishiyama Y, Takahashi H, Masunaga Y, Hachimura S, et al. Identification of multiple isolated lymphoid follicles on the antimesenteric wall of the mouse small intestine. J Immunol. 2002;168(1):57–64.
ไวรัสโคโรนา (โควิด-19) [Internet]. Google News. [cited 2022 Jul 12]. Available from: https://news.google.com/covid19/map?hl=th&gl=TH&ceid=TH:th
Attaway AH, Scheraga RG, Bhimraj A, Biehl M, Hatipoğlu U. Severe covid-19 pneumonia: pathogenesis and clinical management. BMJ. 2021;372:n436.
Fajgenbaum DC, June CH. Cytokine Storm. Longo DL, editor. N Engl J Med. 2020;383(23):2255–73.
Choi H, Shin EC. Hyper-inflammatory responses in COVID-19 and anti-inflammatory therapeutic approaches. BMB Rep. 2022;55(1):11–9.
RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021;384(8):693–704.
Hikmet F, Méar L, Edvinsson Å, Micke P, Uhlén M, Lindskog C. The protein expression profile of ACE2 in human tissues. Mol Syst Biol. 2020;16(7):e9610.
Megyeri K, Dernovics Á, Al-Luhaibi ZII, Rosztóczy A. COVID-19-associated diarrhea. World J Gastroenterol. 2021;27(23):3208–22.
Santacroce L, Inchingolo F, Topi S, Del Prete R, Di Cosola M, Charitos IA, et al. Potential beneficial role of probiotics on the outcome of COVID-19 patients: An evolving perspective. Diabetes Metab Syndr. 2021;15(1):295–301.
Zuo T, Zhang F, Lui GCY, Yeoh YK, Li AYL, Zhan H, et al. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology. 2020;159(3):944-955.e8.
Keely S, Talley NJ, Hansbro PM. Pulmonary-intestinal cross-talk in mucosal inflammatory disease. Mucosal Immunol. 2012;5(1):7–18.
Barengolts E, Smith ED. Considerations for gut microbiota and probiotics in patients with diabetes amidst the COVID-19 pandemic: A narrative review. Endocr Pract. 2020;26(10):1186–95.
Dhar D, Mohanty A. Gut microbiota and COVID-19- possible link and implications. Virus Res. 2020;285:198018.
Sanders ME. Probiotics: definition, sources, selection, and uses. Clin Infect Dis. 2008;46 Suppl 2:S58-61.
Singh K, Rao A. Probiotics: A potential immunomodulator in COVID-19 infection management. Nutr Res. 2021;87:1–12.
Maldonado Galdeano C, Cazorla SI, Lemme Dumit JM, Vélez E, Perdigón G. Beneficial effects of probiotic consumption on the immune system. Ann Nutr Metab. 2019;74(2):115–24.
Geva-Zatorsky N, Sefik E, Kua L, Pasman L, Tan TG, Ortiz-Lopez A, et al. Mining the human gut microbiota for immunomodulatory organisms. Cell. 2017;168(5):928-943.e11.
Hao Q, Dong BR, Wu T. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev. 2015;(2):CD006895.
Lei WT, Shih PC, Liu SJ, Lin CY, Yeh TL. Effect of probiotics and prebiotics on immune response to influenza vaccination in adults: A systematic review and meta-Analysis of randomized controlled trials. Nutrients. 2017;9(11):E1175.
Fonollá J, Gracián C, Maldonado-Lobón JA, Romero C, Bédmar A, Carrillo JC, et al. Effects of Lactobacillus coryniformis K8 CECT5711 on the immune response to influenza vaccination and the assessment of common respiratory symptoms in elderly subjects: a randomized controlled trial. Eur J Nutr. 2019;58(1):83–90.
Dadras O, Afsahi AM, Pashaei Z, Mojdeganlou H, Karimi A, Habibi P, et al. The relationship between COVID-19 viral load and disease severity: A systematic review. Immun Inflamm Dis. 2022;10(3):e580.
Salaris C, Scarpa M, Elli M, Bertolini A, Guglielmetti S, Pregliasco F, et al. Lacticaseibacillus paracasei DG enhances the lactoferrin anti-SARS-CoV-2 response in Caco-2 cells. Gut Microbes. 2021;13(1):1961970.
Ceccarelli G, Borrazzo C, Pinacchio C, Santinelli L, Innocenti GP, Cavallari EN, et al. Oral bacteriotherapy in patients with COVID-19: A retrospective cohort study. Front Nutr. 2020;7:613928.
Bush CL, Blumberg JB, El-Sohemy A, Minich DM, Ordovás JM, Reed DG, et al. Toward the definition of personalized nutrition: A proposal by the American Nutrition Association. J Am Coll Nutr. 2020;39(1):5–15.
Su GL, Ko CW, Bercik P, Falck-Ytter Y, Sultan S, Weizman AV, et al. AGA Clinical Practice Guidelines on the role of probiotics in the management of gastrointestinal disorders. Gastroenterology. 2020;159(2):697–705.
Kelly CR, Fischer M, Allegretti JR, LaPlante K, Stewart DB, Limketkai BN, et al. ACG clinical guidelines: Prevention, diagnosis, and treatment of Clostridioides difficile infections. Am J Gastroenterol. 2021;116(6):1124–47.
McFarland LV, Kullar R, Johnson S, Sniffen JC, Woolard K, Goldstein EJC. Why do ACG and AGA guidelines differ for the use of probiotics and the prevention of CDI? Am J Gastroenterol. 2022;117(3):501.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 SPENT
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The content and information in the articles published in Thai JPEN วารสารโภชนบำบัด, are the opinions and responsibility of the authors directly. The editorial team is not obliged to agree or take any responsibility.
All articles, content, figures, etc. that have been published in Thai JPEN วารสารโภชนบำบัด are the copyright of Thai JPEN วารสารโภชนบำบัด. If any person or organization require distribution of all or any part of them, please send the request for the written permission from Thai JPEN วารสารโภชนบำบัด only.
